Mastercard Inc (MA) Stock News

IMAX stock reached an all-time high driven by the exceptional success of Christopher Nolan's The Odyssey, which became the highest-grossing IMAX release ever. The company reported strong H1 2026 results with 12% revenue growth and 65% earnings growth, while installing 38 premium theater systems at its fastest second-quarter pace in a decade. Analyst Steve Frankel expects results to exceed Wall Street estimates in H2 2026, bolstered by The Odyssey's continued performance and the upcoming Dune: Part Three release.

IMAX Corporation's Chief Technology Officer Pablo Calamera sold 15,000 common shares on August 20, 2026, reducing his direct stake by 26% at a weighted average price of $52.41 per share. The sale occurred as IMAX stock surged 105% over the trailing 12-month period, driven by strong Q2 earnings with 12% revenue growth and Christopher Nolan's 'The Odyssey' becoming the highest-grossing IMAX film ever. Despite the sale, Calamera retains 43,012 common shares and 20,840 RSUs, maintaining significant alignment with shareholder interests.

NEWSMAKER Who is Khalil Al-Hayya, the Hamas leader who met Kushner in Cairo?  Reuters

EU curbs on Chinese solar inverters to bolster European suppliers, SMA Solar says  Reuters

China’s C919 has made its first scheduled international commercial flight, a milestone in COMAC’s bid to challenge Boeing and Airbus globally.

IMAX stock surged 4.33% on Monday after announcing that Christopher Nolan's 'The Odyssey' became the highest-grossing IMAX release of all time with $289 million in ticket sales. The film continues to sell out weeks in advance with nearly $40 million in presales, and IMAX expects this to be its best year ever at the global box office.

Crédit Agricole Brie Picardie reported weekly share buybacks conducted under MAR Regulation Article 5 from August 3-7, 2026, with volumes ranging from 1,537 to 3,692 shares daily at prices between €36.41 and €36.89. The company's Board of Directors met on July 29, 2026 to approve semi-annual financial statements as of June 30, 2026.

Rosen Law Firm reminds investors of the August 10, 2026 deadline to join a securities class action lawsuit against ADMA Biologics. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls that artificially inflated revenue during the class period from August 9, 2024 to March 25, 2026.

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Manhattan Associates, Inc. The firm is seeking shareholders who own MANH stock to contact them regarding their legal rights. Investors can reach out via the firm's website or contact information provided.

ADMA Biologics is facing a securities fraud class action lawsuit alleging misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report in March 2026 revealed channel stuffing and improper accounting practices, causing the stock to plunge 31.6% over two trading days. The lawsuit covers the period from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.

Klépierre, Europe's leading shopping mall operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million. The company demonstrated strong execution in a dynamic retail market, driving organic growth. As of July 31, 2026, the company had 286.86 million shares outstanding.

Klépierre, Europe's leading shopping center operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million and improved net current cash flow per share. The company demonstrated strong execution in a dynamic retail market, driving organic growth across its portfolio of over 720 million annual visitors.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million in 5.375% Sustainability Linked Bonds due May 28, 2027. The early redemption is scheduled for August 24, 2026, with the redemption amount to be calculated and published by August 18, 2026. The bonds will be delisted from Euronext following redemption.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million of 5.375% Sustainability Linked Bonds due 28 May 2027. The redemption will occur on 24 August 2026, with the make-whole redemption amount to be calculated and published around 18 August 2026. All redeemed notes will be cancelled and delisted from Euronext.

ADMA Biologics is facing a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth in 2025 was artificially inflated, with actual revenue declining 3% when adjusted for extended payment terms. The stock declined over 16% following the report, and an additional 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by Monday, August 10, 2026.

Class action lawsuits have been filed against four publicly-traded companies for alleged securities fraud. Futu Holdings faces allegations of non-compliance with Chinese regulatory requirements, First Solar allegedly overstated its ability to manage tariff impacts, Black Rock Coffee Bar allegedly misrepresented its expansion strategy and cannibalization effects, and ADMA Biologics allegedly engaged in undisclosed related party transactions and channel stuffing. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against ADMA Biologics, Inc. following allegations of channel stuffing and undisclosed related party transactions. Culper Research reported that ADMA induced distributors to stock excess inventory through rebates and extended payment terms to artificially inflate revenue growth. The stock fell 29.1% on the news, and investors have until August 10, 2026 to file a lead plaintiff motion.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. alleging misrepresentations concerning financial condition, revenue recognition, and undisclosed related-party transactions. The lawsuit covers the period from August 9, 2024 to March 25, 2026. Following a short-seller report by Culper Research on March 24, 2026 revealing channel stuffing and undisclosed distributor Genesis BioPharma, ADMA's stock plummeted 31.6% over two trading days, with further declines following a rating downgrade.

Wolf Popper LLP filed a securities class action lawsuit against Smartsheet Inc. on behalf of shareholders who sold stock between June 1 and September 23, 2024. The lawsuit alleges that Smartsheet failed to disclose material information about acquisition offers from Blackstone and Vista Equity Partners ($56.25-$56.50 per share) while simultaneously repurchasing its own stock at significantly lower market prices (~$46.45 average). The merger eventually closed on January 22, 2025, at $56.50 per share.

Kahn Swick & Foti, LLC announces a class action securities lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. The application deadline to request lead plaintiff status is August 10, 2026.

The FAA finally certified Boeing's 737 MAX 7 on Monday, seven years after the original 2019 target. The certification clears the way for Boeing to deliver approximately 30 completed aircraft in storage. While the approval is significant for unlocking revenue, the stock's 8% rally was also driven by cheaper oil and a BNP Paribas upgrade. The analyst suggests most of the positive impact is already priced in, with meaningful revenue impact expected in 2027.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

Madonna performed at CLUB CONFESSIONS presented by MISTR during WorldPride Amsterdam on August 4, 2026, surprising fans with a special appearance by Kylie Minogue. The pair debuted a new version of 'Love Sensation' and performed 'Sorry' for the first time in over two decades. The event highlighted Madonna's continued support for the LGBTQ+ community and MISTR's free telemedicine platform offering HIV prevention and sexual healthcare services.

US FAA certifies Boeing 737 MAX 7 in win for planemaker  Reuters

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics (NASDAQ: ADMA) alleging the company artificially inflated stock value through misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A Culper Research short-seller report in March 2026 revealed channel stuffing and undisclosed distributor Genesis BioPharma, causing the stock to plunge 31.6% over two trading days, with further declines following a Cantor Fitzgerald downgrade.

IMAX stock surged 6.60% as the company reported record-breaking performance driven by Christopher Nolan's 'The Odyssey,' which generated $221 million in IMAX ticket sales in July alone. The film achieved the fastest IMAX release to reach $200 million in ticket sales and propelled IMAX to its most successful month in history with $257 million in box-office revenue, 47% higher than the previous record. The company also announced an upcoming IMAX run for 'Spider-Man: Brand New Day' following strong openings in Asian markets.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

IMAX stock continues to rise as Christopher Nolan's film 'The Odyssey,' shot entirely with IMAX cameras, becomes a global cultural phenomenon. The film achieved a record-breaking $52 million opening weekend followed by $48 million in its second weekend, with fans traveling across countries to experience it in IMAX 70mm format. Screenings are selling out around the clock, prompting IMAX to extend 70mm showings into mid-September.

A new AI power bloc called MANGOS is emerging across public and private markets, potentially challenging the dominance of the Magnificent Seven. The group includes companies controlling AI models, compute, and distribution, with Nvidia serving as one of three public-market gateways into this private-heavy AI group.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.